|
Company data displayed is for sample purposes only and may not reflect the most current information available on Emerging Markets Information Service (EMIS).
Kalbe Farma Tbk, PT
Main Activities: Pharmaceutical and Medicine Manufacturing
 |
Please check the full coverage of information what EMIS can offer you. | SEE SAMPLE |
Company Information |
|
Full name Kalbe Farma Tbk, PT Headquarters Kawasan Industri Delta Silicon Jln MH Thamrin Blok A3-1 Lippo Cikarang; Bekasi; West Java; 17550 |
Status: Listed Legal Form: Public Limited Company Operational Status: Operational ISIN CODE : ID1000096803 Financial Auditors: Purwantono, Suherman & Surja (2011) Incorporation Date: September 10, 1966 Total Employees: 9,372 Tel: (62 21) 89907333 |
|
Company Description |
| PT Kalbe Farma Tbk (KLBF) is Indonesia's leading pharmaceuticals manufacturer with approximately 400 brands of pharmaceutical products, comprising of more than 50 OTC products, 20 health foods and 300 ethical products present in 26 provinces. The company started its commercial operations in 1966. The Company's was established on September 10, 1966. KLBF has penetrated a total of 28 international markets, contributing 10% of the group's annual turnover. KLBF retains strategic alliances through its | ||
|
||
Company Analysis |
| According to the Consolidated - Non-Audited financial statement for the first three cumulated quarters of 2012, total net operating revenues increased with 26.25%, from IDR 7,698,024,685 thousands to IDR 9,718,695,032 thousands. Operating result increased from IDR 1,383,088,128 thousands to IDR 1,572,420,608 thousands which means 13.69% change. The results of the period increased 16.68% reaching IDR 1,242,623,360 thousands at the end of the period against IDR 1,065,020,224 thousands last year. Return on equity (Net income/Total equity) went from 17.54% to 18.09%, the Return On Asset (Net income / Total Asset) went from 14.17% to 14.21% and the Net Profit Margin (Net Income/Net Sales) went from 13.83% to 12.79% when compared to the same period of last year. The Debt to Equity Ratio (Total Liabilities/Equity) was 31.73% compared to 28.40% of last year. Finally, the Current Ratio (Current Assets/Current Liabilities) went from 4.07 to 3.40 when compared to the previous year. |
Key Executives |
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
|
|||||
Companies with Similar Main Activities |
FULL COMPANY PROFILE
|
|
2012 Y (cons) |
2012 Q3C (cons) |
|
 | ||
| Audited | Non-Audited | |
| ||
| WVB Company Financials | WVB Company Financials | |
| ||
| Unit | Millions | Millions |
| ||
Balance Sheet
| ||
Total Assets |
9,417,957 |
8,745,245 |
| ||
Current Assets |
6,441,710 |
5,914,266 |
| ||
Total Liabilities |
2,046,313 |
2,179,665 |
| ||
Shareholders Equity |
7,371,643 |
6,870,305 |
| ||
Current Liabilities |
1,891,617 |
1,738,284 |
| ||
| * All the accounts are in IDR. | ||
Income Statement
| ||
Total Operating Revenue |
13,636,405 |
9,718,695 |
| ||
Operational Profit (Loss) |
2,212,409 |
1,572,420 |
| ||
Net Profit (Loss) |
1,733,928 |
1,242,623 |
| ||
| * All the accounts are in IDR. | ||
Ratios
| Profitability Ratios | ||
| ||
Return on Assets (ROA) |
18.41% |
14.21% |
| ||
Annualised Return on Assets (ROA) |
18.41% |
18.95% |
| ||
Return on Equity (ROE) |
23.52% |
18.93% |
| ||
Annualised Return on Equity (ROE) |
23.52% |
25.24% |
| ||
Return on Sales (ROS) |
12.72% |
12.82% |
| ||
Return on Capital |
23.52% |
18.93% |
| ||
Gross Profit Margin |
47.91% |
48.72% |
| ||
Operating Profit Margin |
20.41% |
20.63% |
| Efficiency Ratios | ||
| ||
Accounts Receivable Turnover |
7.55x |
5.69x |
| ||
Inventory Turnover |
3.36x |
2.30x |
| ||
Current asset turnover |
2.12x |
1.64x |
| ||
Fixed-asset turnover |
4.58x |
3.42x |
| ||
Asset Turnover |
1.45x |
1.11x |
| Valuation figures and ratios | ||
| ||
Earning Before Interests and Taxes (EBIT) |
2,217,760 |
1,608,928 |
| ||
EBITDA |
2,339,738 |
1,709,220 |
| ||
Enterprise value |
8,905,712 |
46,781,008 |
| ||
Enterprise Value / EBITDA |
3.81 |
27.37 |
| ||
Bookvalue (BV) |
9,417,957 |
8,629,551 |
| ||
Net Cash |
-31,955 |
-365,605 |
| Liquidity Ratios | ||
| ||
Current Ratio |
340.54% |
340.24% |
| ||
Quick ratio |
228.71% |
215.98% |
| ||
Doom's day ratio |
98.31% |
78.97% |
| Leverage Ratios | ||
| ||
Leverage ratio |
127.76% |
133.2% |
| ||
Interest Coverage Ratio |
12,663.06% |
15,815.72% |
| ||
Debt to equity |
27.76% |
33.2% |
| ||
Debt to total assets |
21.73% |
24.92% |
| ||
Long Term Debt to Capital |
23.35% |
46.5% |
| ||
Debt / Enterprise Value |
0% |
0.25% |
| Market ratios | ||
| ||
Market Capitalization/EBITDA |
4.60 |
27.93 |
| ||
Price/Book Ratio |
1.14 |
5.53 |
| ||
Market Cap / Net cash |
-336.89 |
-130.56 |
| Trend Ratios | ||
| ||
Revenue Trend |
124.97% |
126.03% |
| ||
Net Income Trend |
116.98% |
116.68% |
| ||
Operating Income Trend |
112.69% |
114.04% |
| ||
 |